Q-omics provides the consensus-scored LINC01840 profile across patient tissues and cancer cell-line models. LINC01840 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LINC01840 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, LINC01840 RNA expression shows 6,558 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LGG, COAD, and STAD as cancer lineages where LINC01840 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01840 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01840 survival associations across molecular data types. LINC01840 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01840 RNA expression–survival associations across cancer types. High LINC01840 expression shows unfavorable associations in KIRP, MESO and LIHC, but favorable associations in LGG, LAML and LUAD. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LINC01840 RNA expression.
This table summarizes LINC01840 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01840. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01840 shows lower tumor expression in KIRC, HNSC and KIRP and higher tumor expression in COAD. The COAD box plot shows higher LINC01840 RNA expression in tumor versus normal tissue (log2 FC = +0.492, t-test p < 0.001).
This table shows molecular features associated with LINC01840 in patient tissues and cancer cell lines. In patient samples, LINC01840 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
